Developer docs
API playgroundTry for free, no card

Search company profiles

Quadrant Biosciences

Full company profile

uuid0002hjf

Namestring
Quadrant Biosciences
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Quadrant Biosciences was a Syracuse, NY-based epigenetic diagnostics company that developed autism screening technology for early detection of neurological disorders in children; the company has since filed for bankruptcy and ceased operations.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSyracuse, United States
HQ citystring
Syracuse
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic diagnostics, autism screening, neurological disorder detection, clinical laboratory testing, epigenetic biomarker analysis
Industry3 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Epigenetic Diagnostics
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Quadrant Biosciences developed epigenetic diagnostic tests focused on the early detection of neurological disorders, with autism screening as its primary use case. The company operated a CLIA-certified clinical laboratory and processed saliva-based samples to generate screening insights for healthcare providers. Its offering combined proprietary epigenetic biomarker analysis with clinical laboratory services.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Autism Screening Service (Epigenetic Diagnostic)
CategoryClinical Diagnostics / Epigenetic Diagnostics
Description

Clinical laboratory-based epigenetic diagnostic screening service for early detection of neurological disorders (with autism screening as the primary use case), delivered through a CLIA-certified laboratory and processed via saliva-based sample analysis for healthcare providers and patients.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Pediatric diagnostics company historically focused on genetic and epigenetic testing for autism spectrum disorder and other neurodevelopmental conditions, making it the closest like-for-like competitor to Quadrant's autism screening offering.

TypeBroad incumbent
Description

Established molecular diagnostics company offering genetic and genomic tests across multiple therapeutic areas; provides a benchmark for CLIA-validated DNA/RNA-based testing infrastructure and reimbursement strategy similar to what Quadrant pursued.

TypeBroad incumbent
Description

Public molecular diagnostics company specializing in cell-free DNA and broader genetic testing; comparable on operating a proprietary CLIA lab, assay development pipeline, and pediatric/oncology screening commercial model.

TypeBroad incumbent
Description

Large reference laboratory offering extensive neurodevelopmental and pediatric testing services including autism-related diagnostics; sets the bar for national distribution and payer contracts that a startup epigenetic diagnostics company would need to match.

TypeBroad incumbent
Description

National clinical reference lab with a broad molecular and genetic diagnostics menu, including pediatric and neurological testing, and provides a benchmark for operational scale and reimbursement relationships relevant to Quadrant's CLIA-based business.

TypeEmerging player
Description

Clinical genetic testing company now part of the BioReference network, focused on rare disease and pediatric genomic diagnostics; overlaps with Quadrant in pediatric neurology-oriented testing channels and the build-out of high-complexity CLIA assays.

TypeRegional player
Description

Academic-affiliated reference laboratory with deep neurology and genetics test menus; comparable on operating a CLIA-certified lab serving pediatric and academic medical center customers who order autism and related neurodevelopmental workups.

TypeOthers
Description

Life science tools and clinical diagnostics manufacturer whose molecular and quality-control products are used by labs like Quadrant's; relevant as an infrastructure/upstream peer rather than a direct testing competitor.

TypeEmerging player
Description

Data-driven genomic and clinical analytics company used by hospitals and labs for genomic testing workflows; comparable as a peer leveraging software and analytics layers on top of molecular diagnostic assays for clinical decision-making.

10PerkinElmer
TypeOthers
Description

Diagnostics and life sciences company offering genetic screening, newborn screening, and laboratory instruments; comparable as an incumbent in the epigenetic/genetic testing stack and laboratory automation Quadrant would have relied on.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quadrant Biosciences

Epigenetic Diagnosticsquadrantbiosciences.com

Quadrant Biosciences was a Syracuse, NY-based epigenetic diagnostics company that developed autism screening technology for early detection of neurological disorders in children; the company has since filed for bankruptcy and ceased operations.

Quadrant Biosciences firmographics

Firmographics
Name
Quadrant Biosciences
Website
https://quadrantbiosciences.com
Company type
Private
Founded year
2015
Operating status
Closed
Headcount range
51–100 employees
Short description
Quadrant Biosciences was a Syracuse, NY-based epigenetic diagnostics company that developed autism screening technology for early detection of neurological disorders in children; the company has since filed for bankruptcy and ceased operations.
Ownership category
akta.pro rank

Quadrant Biosciences industry classification

Industry
Product category
Epigenetic Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)

Keywords

  • Epigenetic diagnostics
  • Autism screening
  • Neurological disorder detection
  • Clinical laboratory testing
  • Epigenetic biomarker analysis

Where Quadrant Biosciences is headquartered

Location

Headquarters

HQ city
Syracuse
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quadrant Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Quadrant Biosciences product offering

Product offering

Core offering

Quadrant Biosciences developed epigenetic diagnostic tests focused on the early detection of neurological disorders, with autism screening as its primary use case. The company operated a CLIA-certified clinical laboratory and processed saliva-based samples to generate screening insights for healthcare providers. Its offering combined proprietary epigenetic biomarker analysis with clinical laboratory services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Autism Screening Service (Epigenetic Diagnostic) Clinical laboratory-based epigenetic diagnostic screening service for early detection of neurological disorders (with autism screening as the primary use case), delivered through a CLIA-certified laboratory and processed via saliva-based sample analysis for healthcare providers and patients.

Companies that use Quadrant Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Quadrant Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Quadrant Biosciences partnerships and signals

Strategic signal

Scale indicators1 record

Quadrant Biosciences competitors and assessment

Company assessment

Direct peers

  • Lineagen: Pediatric diagnostics company historically focused on genetic and epigenetic testing for autism spectrum disorder and other neurodevelopmental conditions, making it the closest like-for-like competitor to Quadrant's autism screening offering.

Broad incumbents

  • Myriad Genetics: Established molecular diagnostics company offering genetic and genomic tests across multiple therapeutic areas; provides a benchmark for CLIA-validated DNA/RNA-based testing infrastructure and reimbursement strategy similar to what Quadrant pursued.
  • Natera: Public molecular diagnostics company specializing in cell-free DNA and broader genetic testing; comparable on operating a proprietary CLIA lab, assay development pipeline, and pediatric/oncology screening commercial model.
  • Quest Diagnostics: Large reference laboratory offering extensive neurodevelopmental and pediatric testing services including autism-related diagnostics; sets the bar for national distribution and payer contracts that a startup epigenetic diagnostics company would need to match.
  • Laboratory Corporation of America (Labcorp): National clinical reference lab with a broad molecular and genetic diagnostics menu, including pediatric and neurological testing, and provides a benchmark for operational scale and reimbursement relationships relevant to Quadrant's CLIA-based business.

Emerging players

  • GeneDx: Clinical genetic testing company now part of the BioReference network, focused on rare disease and pediatric genomic diagnostics; overlaps with Quadrant in pediatric neurology-oriented testing channels and the build-out of high-complexity CLIA assays.
  • Sophia Genetics: Data-driven genomic and clinical analytics company used by hospitals and labs for genomic testing workflows; comparable as a peer leveraging software and analytics layers on top of molecular diagnostic assays for clinical decision-making.

Regional players

  • ARUP Laboratories: Academic-affiliated reference laboratory with deep neurology and genetics test menus; comparable on operating a CLIA-certified lab serving pediatric and academic medical center customers who order autism and related neurodevelopmental workups.

Others

  • Bio-Rad Laboratories: Life science tools and clinical diagnostics manufacturer whose molecular and quality-control products are used by labs like Quadrant's; relevant as an infrastructure/upstream peer rather than a direct testing competitor.
  • PerkinElmer: Diagnostics and life sciences company offering genetic screening, newborn screening, and laboratory instruments; comparable as an incumbent in the epigenetic/genetic testing stack and laboratory automation Quadrant would have relied on.

Market position

Customer concentration

Quadrant Biosciences social profiles

Digital presence

Quadrant Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quadrant Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Quadrant Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quadrant Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quadrant Biosciences

What does Quadrant Biosciences do?

Quadrant Biosciences developed epigenetic diagnostic tests focused on the early detection of neurological disorders, with autism screening as its primary use case. The company operated a CLIA-certified clinical laboratory and processed saliva-based samples to generate screening insights for healthcare providers. Its offering combined proprietary epigenetic biomarker analysis with clinical laboratory services.

Is Quadrant Biosciences a public or private company?

Quadrant Biosciences is a private company. It is classified as venture growth investor backed and is currently closed.

When was Quadrant Biosciences founded?

Quadrant Biosciences was founded in 2015. It employs 51 to 100 people.

Where is Quadrant Biosciences based?

Quadrant Biosciences is headquartered in Syracuse, United States, in the North America region.

Who are Quadrant Biosciences's main competitors?

Lineagen is listed as a direct peer. Broad incumbents are Myriad Genetics, Natera, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Emerging players are GeneDx and Sophia Genetics. ARUP Laboratories is listed as a regional player. Others are Bio-Rad Laboratories and PerkinElmer.

Does Quadrant Biosciences have an API?

No public API is recorded for Quadrant Biosciences.

What industry is Quadrant Biosciences in?

Quadrant Biosciences's product category is Epigenetic Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGANAF, Epigenomics & Chromatin Profiling Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Post-StandardSyracuse biotech accelerator gets $3M to add space for startups (Good Morning CNY for Jan. 28)The Central New York Biotech Accelerator in Syracuse received $3 million in state funding to add laboratory space for startups. The funding comes after the accelerator lost its largest tenant, Quadrant Biosciences—an autism screening company that went bankrupt—creating a need to retool and attract new startups. The investment represents a recovery effort to rebuild the accelerator's tenant base following the significant setback.Blockchain App FactoryWhy Businesses Are Using Tokenization for Growth in 2025The article analyzes the growing adoption of tokenization as a financing mechanism, highlighting that the global tokenization market is projected to reach nearly $4 billion in 2025 with an 18–22% annual growth rate. It details how businesses utilize various token types, such as security and utility tokens, to unlock illiquid assets, democratize ownership, and access global capital more efficiently than traditional methods like IPOs or VC rounds. Real-world applications are illustrated through examples including RealT in real estate, INX in regulated securities, and Quadrant Biosciences in biotech.PR NewswirePatent Awarded for Saliva-Based Test to Help Diagnose Concussion and Predict Duration of SymptomsQuadrant Biosciences and its academic partners, the State University of New York Research Foundation and the Penn State Research Foundation, have been awarded U.S. Patent No. 11,453,914 by the USPTO for saliva-based analysis and prediction of mild traumatic brain injury and concussion symptoms.PR NewswireNow Available in Kentucky: New Virtual Clinic Focuses on Diagnosing Autism SoonerQuadrant Biosciences Inc. has launched 'As You Are,' a new virtual clinic in Kentucky and four other states designed to reduce autism diagnosis wait times from years to less than one month through telehealth appointments. The service targets children aged 16 months to 10 years, aiming to address the shortage of diagnostic resources in over 80% of U.S. counties by providing rapid, evidence-based evaluations.PR NewswireNow Available in Pennsylvania: New Virtual Clinic Focuses on Diagnosing Autism SoonerAs You Are, a new virtual clinic operated by Quadrant Biosciences Inc., launched on August 1, 2022, in Alabama, Kentucky, New Jersey, Ohio, and Pennsylvania, offering telehealth-based autism evaluations for children 16 months to 10 years old. The service reduces autism diagnosis time from 12-30 months to less than 30 days, addressing what the company calls a critical gap as over 80% of U.S. counties currently lack diagnostic resources. The clinic plans to expand nationwide as it works to provide earlier interventions for children during the critical developmental period.PR NewswireNow Available in New Jersey: New Virtual Clinic Focuses on Diagnosing Autism SoonerA new virtual clinic called As You Are launched on August 1, 2022, in five U.S. states (Alabama, Kentucky, New Jersey, Ohio, Pennsylvania), offering telehealth-based autism evaluations for children aged 16 months to 10 years. The clinic aims to address significant diagnostic delays by reducing wait times from the typical 12–30 months to under 30 days, as over 80% of U.S. counties currently lack diagnostic resources for autism. The service is managed and operated by Quadrant Biosciences Inc., a life sciences company headquartered in Syracuse, New York, with plans for nationwide expansion.PR NewswireNow Available in Alabama: New Virtual Clinic Focuses on Diagnosing Autism SoonerA new virtual clinic called As You Are has launched in Alabama and four other states, offering telehealth-based autism evaluations for children 16 months to 10 years old. The clinic aims to reduce autism diagnosis wait times from 12-30 months to under 30 days, addressing what the company calls a critical need given that over 80% of U.S. counties lack diagnostic resources. As You Are is managed and operated by Quadrant Biosciences Inc., a life sciences company headquartered in Syracuse, New York, with plans to expand nationwide.PR NewswireNow Available in Ohio: New Virtual Clinic Focuses on Diagnosing Autism SoonerAs You Are, a new virtual clinic providing telehealth-based autism evaluations for children 16 months to 10 years old, launched on August 1, 2022 in Alabama, Kentucky, New Jersey, Ohio, and Pennsylvania. The clinic, managed by Quadrant Biosciences Inc., aims to reduce autism diagnosis wait times from 12–30 months to under 30 days, addressing what executives describe as a critical gap with over 80% of U.S. counties lacking diagnostic resources. The company plans to expand the service nationwide and is headquartered in Syracuse, New York.BioSpaceDr. Funda Suer Joins Quadrant Biosciences as EVP of Clinical Diagnostics and CLIA Laboratory DirectorQuadrant Biosciences announced Dr. Funda Suer's appointment as Executive Vice President of Clinical Diagnostics and CLIA Laboratory Director. She will lead Laboratory Services and expand the company's molecular genetic testing portfolio, having previously served at Mount Sinai Genomics and Sem4.PR NewswireDr. Funda Suer Joins Quadrant Biosciences as EVP of Clinical Diagnostics and CLIA Laboratory DirectorQuadrant Biosciences Inc. announced the appointment of Dr. Funda Suer as Executive Vice President of Clinical Diagnostics and CLIA Laboratory Director, effective immediately. Dr. Suer brings extensive experience in molecular genetic testing from her previous role as Senior Director of Clinical Laboratory at Mount Sinai Genomics, Sem4, and will lead the company's laboratory services in developing and adopting new diagnostic assays. The company stated Dr. Suer will be instrumental in expanding Quadrant's molecular testing portfolio focused on autism spectrum disorder, concussion injuries, and Parkinson's disease.